Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
22.06
-0.32 (-1.43%)
At close: Aug 29, 2025, 4:00 PM
22.08
+0.02 (0.09%)
After-hours: Aug 29, 2025, 4:20 PM EDT
Celldex Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts that cover Celldex Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $46.13, which forecasts a 109.11% increase in the stock price over the next year. The lowest target is $31 and the highest is $67.
Price Target: $46.13 (+109.11%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Celldex Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Hold | 3 | 3 | 3 | 3 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $44 → $38 | Buy | Maintains | $44 → $38 | +72.26% | Aug 20, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $56 → $48 | Strong Buy | Maintains | $56 → $48 | +117.59% | Aug 20, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $64 → $62 | Strong Buy | Maintains | $64 → $62 | +181.05% | Aug 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $50 → $42 | Strong Buy | Maintains | $50 → $42 | +90.39% | Aug 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +126.65% | Jun 16, 2025 |
Financial Forecast
Revenue This Year
3.93M
from 7.02M
Decreased by -44.09%
Revenue Next Year
3.51M
from 3.93M
Decreased by -10.65%
EPS This Year
-3.54
from -2.45
EPS Next Year
-4.21
from -3.54
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 10.2M | 12.6M | |||
| Avg | 3.9M | 3.5M | |||
| Low | 1.4M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 45.1% | 221.0% | |||
| Avg | -44.1% | -10.6% | |||
| Low | -80.5% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.22 | -3.69 | |||
| Avg | -3.54 | -4.21 | |||
| Low | -3.81 | -4.69 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.